Comparison

Olverembatinib European Partner

Manufacturer MedChem Express
Category
Type Inhibitors
Specific against other
Amount 25mg
Item no. HY-15666-25mg
CASRN 1257628-77-5
Available
Product Description
Olverembatinib (GZD824) is a potent and orally active pan-Bcr-Abl inhibitor. Olverembatinib potently inhibits a broad spectrum of Bcr-Abl mutants. Olverembatinib strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. Olverembatinib has antitumor activity.
StorageTemperature
Powder -20°C 3 years, 4°C 2 years; In solvent -80°C 6 months, -20°C 1 month
Applications
Cancer-Kinase/protease
Formula
C29H27F3N6O
References
[1].Ren X, Pan X, Zhang Z, Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem. 2013 Feb 14; 56(3):879-94.
MolecularWeight
532.56
Research Area
Cancer
Solubility
DMSO : 50 mg/mL (93.89 mM; Need ultrasonic)
Target
Bcr-Abl
Pathway
Protein Tyrosine Kinase/RTK

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

Amount: 25mg
Available: In stock
available

Delivery expected until 4/13/2023 

Compare

Add to wishlist

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close